MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis
Launched by HVIDOVRE UNIVERSITY HOSPITAL · Feb 18, 2018
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
MR-elastography and Phase Contrast MRI compared to LVC
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with cirrhosis and esophageal varices that require NSBB treatment
- • Patients of more than 18 and less than 78 years of age
- • Patients with a portal pressure HVPG ≥ 12mmHg
- Exclusion Criteria:
- • Patients who are unable to give informed consent
- • Patients with absolute contraindication for MRI
- • Patients with absolute contraindication for NSBB
- • Pregnant women
- • Patient with severe hemodynamic comorbidity
About Hvidovre University Hospital
Hvidovre University Hospital is a leading clinical research institution located in Denmark, dedicated to advancing medical science through rigorous clinical trials and innovative healthcare solutions. As a prominent academic hospital, it integrates patient care with research, fostering collaboration among multidisciplinary teams of healthcare professionals, researchers, and academic institutions. Hvidovre University Hospital is committed to enhancing patient outcomes by conducting high-quality clinical studies across various therapeutic areas, ensuring adherence to ethical standards and regulatory compliance. Its state-of-the-art facilities and focus on translational medicine position the hospital as a key player in the development of new treatments and therapies, ultimately contributing to the improvement of public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hvidovre, , Denmark
Patients applied
Trial Officials
Flemming Bendtsen, Professor
Principal Investigator
Professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials